UOC of Dermatology, Policlinico Umberto I, Sapienza Medical School of Rome, Rome, Italy.
Department of Dermatology, Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary.
Dermatol Ther. 2019 Sep;32(5):e13043. doi: 10.1111/dth.13043. Epub 2019 Aug 16.
Nonmelanoma skin cancer is the most common malignant tumor in the fair skin population, with each year several millions of diagnosed cases. Their most common risk factors are fair skin, a history of excessive ultraviolet light exposure, chronic inflammatory skin conditions, exposure to radiation, and contact with arsenic. Certain drugs can also be associated with a higher risk of nonmelanoma skin cancer. These include hydroxyurea, which acts as a metabolic inhibitor of ribonucleotide reductase and a potent nonalkylating myelosuppressive agent. It is used for the treatment of various myeloproliferative disorders, including chronic myeloid leukemia, polycythemia vera, and essential thrombocytopenia. Several publications describe an increased occurrence of skin manifestations following hydroxyurea treatment. A growing body of evidence indicates a possible role of hydroxyurea in skin cancer progression. In this review article, we summarize some relevant observations about the association of hydroxyurea and skin cancer, and we describe our own clinical experiences to provide up to date recommendations about the care of patients on hydroxyurea therapy.
非黑色素瘤皮肤癌是白种人群中最常见的恶性肿瘤，每年有数百万人被诊断出患有该病。其最常见的危险因素包括浅色皮肤、过度暴露于紫外线、慢性炎症性皮肤病、辐射暴露和接触砷。某些药物也可能与非黑色素瘤皮肤癌的风险增加有关。这些药物包括羟基脲，它作为核苷酸还原酶的代谢抑制剂和有效的非烷化骨髓抑制剂。它用于治疗各种骨髓增生性疾病，包括慢性髓细胞白血病、真性红细胞增多症和特发性血小板增多症。有几篇出版物描述了羟基脲治疗后皮肤表现发生率增加。越来越多的证据表明，羟基脲可能在皮肤癌进展中起作用。在这篇综述文章中，我们总结了一些关于羟基脲与皮肤癌之间关联的相关观察结果，并描述了我们自己的临床经验，以提供关于羟基脲治疗患者护理的最新建议。
